Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Pharmaceuticals


  • Little-Known Investing Gems Wednesday, 7 May 2008 | 12:28 PM ET

    Haim Israel of Merrill Lynch in Jerusalem has some ideas about smaller Israeli companies that might have escaped the attention of U.S. investors.

  • A visit from the fairy

    There's no money left under the pillow, but Amgen execs and directors have been handed a gift. One of the most outspoken, large, individual investors in the biotech company who's been calling for the Board and CEO to go won't be attending its annual shareholder meeting after all.

  • Study Shows Conflicts in Stent Industry Tuesday, 6 May 2008 | 7:40 PM ET
    Heart Stent

    Too few influential doctors are telling the public if they have financial ties to the companies that make lifesaving drug-coated stents.

  • merck_logo.jpg

    After the closing bell yesterday, Merck announced that it plans to get rid of 12-hundred or around 15 percent of its sales reps. Like Schering-Plough, the company is having to adjust to lower sales of its Vytorin and Zetia cholesterol drugs and on top of that the Food and Drug...

  • Alstom in Reported Bribery Investigation Tuesday, 6 May 2008 | 4:36 AM ET

    A host of news out of France on Tuesday, with Alstom down more than 2 percent on reports that officials are investigating it for bribery.

  • Is Bristol-Myers Breaking Up? Monday, 5 May 2008 | 6:22 PM ET

    If so, Cramer says it could be a great move for this company.

  • Chantix Ad

    While thumbing through “Parade” magazine yesterday, the fluffy publication that you find tucked inside some Sunday newspapers, I noticed an ad for Pfizer’s stop-smoking drug Chantix. It caught my eye because the company had stopped doing what’s called “branded” advertising for the pill earlier this year because of new safety concerns...

  • Fixing Pfizer And Your Emails Friday, 2 May 2008 | 2:02 PM ET

    It's the kind of artwork I'm sure they weren't happy to see at Pfizer spacer headquarters this morning. The torn company logo on the front page of the Newark Star-Ledger business section above the headline, "Signs of Wear and Tear."

  • Former Merck CEO Prodding Industry On Drug Pricing Thursday, 1 May 2008 | 10:31 AM ET
    Dr. Vagelos

    I didn't post yesterday because I was in Philadelphia shooting a story for an upcoming episode of "The Business of Innovation" on CNBC. It's a piece about big pharma and we went to Philly to interview the still very busy former CEO of Merck (two CEOs ago), Dr. Roy Vagelos.

  • Patent Law Battle a Boon to Lobbyists Wednesday, 30 Apr 2008 | 11:01 AM ET

    A fight has erupted in Congress over the question of whether drug makers and other companies should be allowed to keep patents they obtained by misrepresentation or cheating, The New York Times reports.

  • European Earnings: Alcatel-Lucent Drops 7% on Results Wednesday, 30 Apr 2008 | 4:32 AM ET
    Alcatel Lucent

    Earnings out of Europe were mixed Wednesday as telecom giant Alcatel-Lucent cuts its telecom market forecast and reported a bigger-than-expected first-quarter net loss.

  • Stocks Fall Ahead of Fed Tuesday, 29 Apr 2008 | 6:13 PM ET

    The markets dropped a bit as investors eagerly await Wednesday's rate decision. Find out what was moving in the Word on the Street.

  • Genentech, Biogen Idec Shares Hit by Study Results Tuesday, 29 Apr 2008 | 12:07 PM ET

    Genentech and Biogen Idec said a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.

  • Merck "Adapts" To Tredaptive Setback Tuesday, 29 Apr 2008 | 11:37 AM ET

    Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.

  • Merck Shares Plunge as Cholesterol Drug Rejected Tuesday, 29 Apr 2008 | 11:20 AM ET

    U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.

  • Forget Fed Watch Monday, 28 Apr 2008 | 6:15 PM ET

    Wall Street’s on the edge of its seat ahead of Wednesday’s interest-rate announcement. You should be on the phone with your broker.

  • Regulatory "Risky Business" for Pharma & Biotech Monday, 28 Apr 2008 | 11:56 AM ET
    Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • Amgen: Is "A" For Anemia Or Acquisition? Friday, 25 Apr 2008 | 12:35 PM ET

    The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.

  • Pfizer's Kindler Doesn't Duck Tough Questions Thursday, 24 Apr 2008 | 1:55 PM ET
    Jeff Kindler, Pfizer Chairman and CEO

    Pfizer held its shareholder meeting Thursday morning at the historic Memphis hotel where the ducks march through the lobby. I haven't seen the spectacle yet, but I'm told it's quite the scene. Watch my exclusive interview with Chairman and CEO Jeff Kindler.

  • AstraZeneca Raises Guidance, Quarterly Sales Light Thursday, 24 Apr 2008 | 7:11 AM ET

    AstraZeneca nudged up its forecast for 2008 earnings on Thursday, but sales of key products in the first quarter were weaker than hoped for, knocking its shares.